First assessment of the performance of an implantable continuous glucose monitoring system through 180 days in a primarily adolescent population with type 1 diabetes.
Ronnie AronsonAlexander AbitbolKatherine S TwedenPublished in: Diabetes, obesity & metabolism (2019)
The Eversense XL CGM system is safe and accurate through 180 days in a primarily adolescent population of subjects with T1D.
Keyphrases